Annual Report 2025

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2025 90 The United Laboratories International Holdings Limited Annual Report 2025 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (b) Other segment information (Continued) For the year ended 31 December 2024 Intermediate Bulk Finished products medicine products Unallocated Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Amortisation of intangible assets 1,925 – 17,561 – 19,486 Depreciation of right-of-use assets 2,872 8,920 3,232 1,154 16,178 Depreciation of property, plant and equipment 355,496 119,603 103,895 889 579,883 Net loss on disposal of property, plant and equipment 1,899 1,667 703 – 4,269 Written off of property, plant and equipment 8,618 7,712 6,967 – 23,297 Write-down of inventories (reversed) recognised (5,641) 793 (11,111) – (15,959) Impairment losses recognised 3,027 7,253 34,432 168 44,880 (c) Geographical information The revenue by geographical market (irrespective of the origin of the goods) based on the location of the customers are presented below: Revenue from external customers 2025 2024 RMB’000 RMB’000 PRC, including Hong Kong (country of domicile) 9,199,205 11,115,585 Europe 2,001,705 695,589 India 439,678 634,347 Middle East 37,649 73,284 South America 843,692 363,284 Other Asian regions 492,848 633,318 Other regions 195,850 243,530 13,210,627 13,758,937